Responses to romidepsin by line of therapy in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL).
Francine M. Foss
Consultant or Advisory Role - Celgene; Eisai; Kyowa Hakko Kirin; Seattle Genetics; Spectrum Pharmaceuticals
Honoraria - Celgene; Spectrum Pharmaceuticals
Research Funding - Celgene
Barbara Pro
Consultant or Advisory Role - Celgene
Honoraria - Celgene
H. Miles Prince
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Lubomir Sokol
Consultant or Advisory Role - Celgene (U)
Research Funding - Gloucester Pharmaceuticals
Matthew Greenwood
No relevant relationships to disclose
Dolores Caballero
No relevant relationships to disclose
Steven M. Horwitz
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium
Research Funding - Celgene; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Millennium; Seattle Genetics; Spectrum Pharmaceuticals
Bertrand Coiffier
Consultant or Advisory Role - Celgene